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Abstract
Background: The primary objective of this study was to determine the maximum tolerated dose (MTD) of escalating doses of
radiotherapy (RT) concomitantly with a fixed dose of gemcitabine (300 mg/m2/week) within the same overall treatment time.
Methods: Thirteen patients were included. Gemcitabine 300 mg/m2/week was administered prior to RT. The initial dose of RT
was 45 Gy in 1.8 Gy fractions, escalated by adding 5 fractions of 1.8 Gy (one/week) to a dose of 54 Gy with a total duration
kept at 5 weeks. All patients received a dynamic MRI to assess the pancreatic respiratory related movements. Toxicity was
scored using the RTOG-EORTC toxicity criteria.
Results: Three of six patients experienced an acute dose limiting toxicity (DLT) at the 54 Gy dose level. For these patients a
grade III gastro-intestinal toxicity (GI) was noted. Patients treated at the 45 Gy dose level tolerated therapy without DLT. The
54 Gy dose level was designated as the MTD and was deemed not suitable for further investigation.
Between both dose levels, there was a significant difference in percentage weight loss (p = 0.006) and also in cumulative GI
toxicity (p = 0.027). There was no grade 3 toxicity in the 45 Gy cohort versus 4 grade 3 toxicity events in the 54 Gy cohort.
The mean dose to the duodenum was significantly higher in the 54 Gy cohort (38.45 Gy vs. 51.82 Gy; p = 0.001).
Conclusion: Accelerated dose escalation to a total dose of 54 Gy with 300 mg/m2/week gemcitabine was not feasible. GI
toxicity was the DLT. Retrospectively, the dose escalation of 9 Gy by accelerated radiotherapy might have been to large. A dose
of 45 Gy is recommended. Considering the good patient outcomes, there might be a role for the investigation of a fixed dose
of gemcitabine and concurrent RT with small fractions (1.8 Gy/day) in borderline resectable or unresectable non-metastatic
locally advanced pancreatic cancer.
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Pancreatic ductal adenocarcinoma has a 5-year survival
rate of 0.4% [1] to 5% [2]. Because of this dismal progno-
sis, it is one of the top four causes of cancer death in the
Western world [3]. Surgical resection of the tumour is
associated with improved 5-year survival up to approxi-
mately 20% [4], but unfortunately, only 10% to 20% of
patients are candidate for surgery at initial diagnosis [5]
and there remains a high incidence of local tumour recur-
rence [6]. Approximately 40% of patients with pancreatic
cancer present with locally advanced non-metastatic dis-
ease. Tumour adherence or invasion into adjacent struc-
tures, particularly the celiac and superior mesenteric
vasculature (T3-4 or stage III disease according to the
TNM-classification) make complete resection difficult or
impossible. The median survival of patients with non-
metastatic locally advanced pancreatic cancer (LAPC) var-
ies between 6 to 12 months when treated with palliative
therapy.
Based on an early trial by the Gastrointestinal Tumour
Study Group, which demonstrated a modest survival ben-
efit with chemoradiotherapy (CRT) when compared to
radiation therapy (RT) or chemotherapy alone, patients
who have unresectable disease are often treated with con-
current fluorouracil (5-FU)-based CRT [7].
Gemcitabine has been shown to provide a survival advan-
tage over 5-FU in patients with locally advanced (unre-
sectable) or metastatic pancreatic cancer [8]. Also,
different in vitro and in vivo studies have demonstrated
that gemcitabine is a potent radiosensitizer in human can-
cer cell lines including pancreatic cancer cell lines [9-12].
Thus integration of gemcitabine with radiation in a CRT
protocol represents an alternative approach to improve
outcome in patients with pancreatic cancer [13].
Based on studies of hyperfractionation and/or accelera-
tion in squamous cell cancer of head and neck [14], one
could expect that the combination of RT dose escalation
and concurrent gemcitabine would also improve the rate
of loco-regional control and in the same time overall sur-
vival in patients with non-metastatic LAPC.
The primary objective of this study was to define the max-
imum tolerated dose (MTD) of escalating doses of RT
delivered concurrently with a fixed dose of gemcitabine
(300 mg/m2) administered on a weekly basis within the
same overall treatment time in patients with borderline
resectable or unresectable LAPC.
Methods
Eligibility
Eligibility criteria for study entry included cytological or
histological confirmation of pancreatic adenocarcinoma.
Patients were required to have T3-4 disease (Tumour
adherence or invasion into adjacent structures, particu-
larly the celiac and superior mesenteric vasculature), N0-
1 according to the TNM-classification, without distant
metastases (M0). Eligible patients were required to be ≥
18 years, to have a WHO performance status ≤ 2 and a life
expectancy of more than 3 months. Pre-treatment evalua-
tion included a complete history and physical examina-
tion, a diagnostic CT scan of the abdomen with
intravenous (IV) contrast, as well as a blood exam with an
adequate haematological (absolute neutrophil count
(ANC) ≥ 1.5 × 103/L, platelets > 100 × 103/L, hemoglobin
level > 10 g/dL), renal (serum creatinin concentration < 2
mg/dL) and liver function (bilirubin ≤ 1.5 times UNL,
SGOT and SGPT ≤ 2.5 times UNL). All patients underwent
an ERCP and also a laparoscopy to exclude peritoneal
metastasis. Patients were excluded for any other concom-
itant cancers or serious illnesses (medical or psychiatric)
and for metastatic disease. This phase I trial was approved
by an independent ethics committee and all patients gave
written informed consent before study enrolment.
Study design
The treatment schedule is shown in Figure 1. Gemcitabine
was administered weekly in a single dose of 300 mg/m2 as
a 30-min IV infusion at least one hour prior to RT. This
dose was chosen based on literature data [13,15,16] and
taking into account that escalating doses of RT would be
given. The starting dose of RT was 45 Gy in 25 fractions of
1.8 Gy per day. Dose escalation was achieved by giving 2
fractions of 1.8 Gy per day on a fixed day, with an inter-
fraction interval of at least 6 hours. The escalating dose
levels we planned to test were: 54 Gy, 59.4 Gy and 63 Gy.
The total duration of the RT was kept on 5 weeks. Five
patients were treated in the first dose cohort and followed
for one month post treatment before entering patients in
subsequent cohorts. We have chosen to escalate the dose
by adding an extra fraction of 1.8 Gy 6 to 8 hours after the
first one on some days instead of increasing the dose per
fraction as smaller fraction sizes induce less late side
effects. Moreover, adding extra fractions on some days did
not prolong overall treatment time. With this accelerated
scheme, we wanted to avoid to prolong the overall treat-
ment time as this may be deleterious (accelerated repopu-
lation) and as these patients have such a poor prognosis
that we did not want to jeopardise their limited survival
by increasing overall treatment time.
Radiotherapy
The dose was prescribed at the centre of the target area or
at the intersection of central rays of the beam. Highly con-
formal beams were used, with at least 5 incident beams
and 18 MV photons. CT-based treatment planning (with
a contrast enhanced CT scan using 5 mm slices) was
required for all patients as well as a dynamic MRI in treat-Page 2 of 7
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ing movement [17]. The clinical target volume (CTV)
included the primary tumour with the peripancreatic and
pathological lymph nodes. The patient specific margins
around the clinical target volume to account for breathing
motion as defined on dynamic MRI were then expanded
with another 1 cm to the planning target volume (PTV).
The supportive care program consisted of a close follow
up (at least weekly) by a medical doctor combined with a
regular consultation with the dietician and prescription of
an anti-emetic therapy (5-HT3 antagonist) whenever
required.
Toxicity criteria
Patients interrupted treatment in case of grade 4 adverse
events. When one of five patients experienced a dose lim-
iting toxicity (DLT) in a stratum, an additional 5 patients
were entered at that dose level. A DLT was defined as one
or more of the following events occurring within 8 weeks
after the start of treatment: any grade 3 gastro-intestinal
(GI) toxicity, any grade 3 liver toxicity that persisted for
more than 2 weeks, pancreatitis, any grade 4 skin toxicity
within the radiation field, an interruption of the course of
RT due to toxicity that lasted more than 2 consecutive
weeks, or if 2 interruptions occurred each of which lasted
at least one week, an interruption of the course of chemo-
therapy due to haematological toxicity for 2 consecutive
weeks (cycles), febrile neutropenia, or any other grade 3
or 4 toxicity. The RT doses were fixed; however, RT was
planned to be interrupted temporarily to manage local
toxicity presented in body areas in the radiation volumes,
especially in case of grade 3 or 4 adverse events involving
small and large intestine. If the toxicity reduced to grade 1
or 2, RT was continued. Based upon the blood counts on
the day of treatment, a 20% dose reduction of gemcitab-
ine was given for ANC > 1.0 × 103/L and < 1.499 × 103/L
and/or platelet count > 50 × 103/L and < 75 × 103/L. A
treatment was dropped for ANC > 0.5 × 103/L and < 0.999
× 103/L and/or platelet count > 20 × 103/L and < 50 ×
103/L. A new treatment cycle could begin when blood
counts were recuperated. When ANC was < 0.5 × 103/L
and/or platelet count < 20 × 103/L, the administration of
gemcitabine was stopped.
Patients were examined and toxicities were scored at least
every week until 4 weeks after the end of treatment. All
toxicities encountered during the course of CRT were eval-
uated using the RTOG-EORTC Common Toxicity Criteria.
The stratum in which DLT were seen, will be defined as
the MTD. The recommended dose of RT was defined as
one level below the MTD.
Treatment scheme: different RT dose levels to be investigatedFigure 1
Treatment scheme: different RT dose levels to be investigated. Radiotherapy dose escalation scheme investigated in 
this phase I trial; gemcitabine (G) was administered on day 1 of week 1, 2, 3, 4 and 5 in a single dose of 300 mg/m2 as a 30-min 
IV infusion at least one hour prior to RT; the starting dose of RT was 45 Gy in 25 fractions of 1.8 Gy per day (XRT); dose esca-
lation was achieved by giving 2 fractions of 1.8 Gy per day on a fixed day, with an interfraction interval of at least 6 hours, an 
arrow indicates an extra fraction of 1.8 Gy on that day; the escalating dose levels tested were: 54 Gy, 59.4 Gy and 63 Gy; the 
total duration of the RT was kept on 5 weeks.
Dose Week 1 Week 2 Week 3 Week 4 Week 5 
 M T W T F M T W T F M T W T F M T W T F M T W T F
45 Gy 





     
 
G 
     
 
G 
     
 
G 
     
 
G 
    
54 Gy 





Ç     
 
G 
Ç     
 
G 




XRT XRT XRT XRT XRT
    
 
G 
Ç    
59.4 Gy 




Ç  Ç   
 
G 
Ç     
 
G 
Ç  Ç   
 
G 
Ç     
 
G 
Ç  Ç  
63 Gy 




Ç  Ç   
 
G 
Ç  Ç   
 
G 
Ç  Ç   
 
G 
Ç      Ç Ç Ç
 
G 
 Page 3 of 7
(page number not for citation purposes)
Radiation Oncology 2008, 3:30 http://www.ro-journal.com/content/3/1/30Surgery
Approximately 4 to 6 weeks after the end of the CRT,
patients were re-evaluated with a CT of the abdomen to
assess resectability. When a patient had become operable,
he/she was referred for surgery. If a patient stayed inoper-
able, treatment with conventional systemic gemcitabine
was given until disease progression or until a total dura-
tion of 6 months. The followed scheme was 1000 mg/m2
per week for 3 consecutive weeks with one week of rest.
Statistical considerations
The study intent was to determinate the DLT of escalating
doses of RT delivered concurrently with a fixed dose of
gemcitabine (300 mg/m2) administered on a weekly basis
within the same overall treatment time. The different
parameters in both of the dose cohorts were compared by
a student's t-test. The relationship between the percentage
weight loss and the cumulative GI toxicity (= sum of all
different GI toxicities) and the total dose administered to
the different normal tissues was evaluated with a Spear-
man rank correlation test. A p-value ≤ 0.05 was considered
to be significant for these tests. Survival was measured
from the day of diagnosis until death or the last date of
follow up.
Results
Patient characteristics and treatment received
Over a 2 year period, 13 patients with locally advanced
histologically proven, T3-T4 or stage III pancreatic adeno-
carcinoma, were enrolled in this study. No patient had
received prior therapy for pancreatic cancer. The median
age of study participants was 58 years (range, 42–70
years). There were 7 men and 6 women. WHO perform-
ance status was 0 in 6, 1 in 5 and 2 in 2 subjects. The
median duration of RT was 37 days (range, 32–40 days).
The median volume of the PTV was 536.7 cm3 (mean of
522.5 cm3), ranging from 200.3 cm3 to 869.0 cm3. The
volume of each PTV is listed in Table 1 per patient.
Five patients were included in the 45 Gy cohort and they
completed the planned treatment without experiencing
any DLT. One patient in this cohort required a dose reduc-
tion of gemcitabine because of haematological toxicity,
but there was no delay in treatment delivery. The next
dose level was then tested and 5 patients were included in
the 54 Gy cohort. All patients were able to complete the
planned treatment, but one patient received only 4 cycles
of gemcitabine. Two of 5 patients experienced a DLT,
which consisted of acute grade 3 GI toxicity (grade 3 nau-
sea for the first patient and grade 3 nausea and vomiting
for the second). An additional 5 patients were planned to
enter this dose level, but the first patient also suffered a
grade 3 GI toxicity (nausea), so dose escalation was inter-
rupted and the 54 Gy dose level was designated as the
MTD and was deemed not suitable for further investiga-
tion. Another 2 patients were then studied at the dose
level below (45 Gy).
Toxicity
All 13 patients were evaluable for toxicity analysis, with
the different GI toxicities experienced per dose cohort dur-
ing CRT shown in Table 2. Although it was not the intent
of the study to perform a formal comparison between the
two dose cohorts (due to the limited number of patients
and the non-randomised setting), we report here differ-
ences and correlations that might be of interest. Between
both dose levels, there was a significant difference in per-
centage weight loss (4.51% ± 2.11 in the 45 Gy cohort and
11.88% ± 5.26 in the 54 Gy cohort; p = 0.006) and also in
cumulative GI toxicity (p = 0.027). There was no grade 3
toxicity in the 45 Gy cohort versus 4 grade 3 toxicity events
in the 54 Gy cohort. There was no significant difference in
the mean dose to the stomach between both dose levels
but the mean dose to the duodenum was significantly
higher in the 54 Gy cohort (38.45 Gy vs. 51.82 Gy; p =
0.001).
Non-resected patients
Eight of the 13 patients did not undergo resection. For
three of these patients, a palliative Roux-en-Y choledocho-
jejunostomy and gastrojejunostomy were performed pre-
CRT. In one patient, it was performed post-CRT because of
the evidence of evolutive disease with a gastric outlet
obstruction and in another patient because of persisting
inoperability at exploratory laparotomy. In the remaining
three patients, there was no possibility for a surgical pro-
cedure and two cases continued with gemcitabine accord-
ing to the study protocol.
Table 1: Volume of PTV per patient and the mean dose to the 
PTV (% of prescribed dose and absolute dose)
PTV (planning target volume)
Patient Volume Mean dose % Mean dose Gy
Patient 1 445.6 99.7 44.9
Patient 2 539.9 100.2 45.1
Patient 3 396 100.1 45.1
Patient 4 590.2 100.4 45.2
Patient 5 637.1 99.1 44.6
Patient 6 200.3 100.5 45.2
Patient 7 318 101 45.5
Patient 8 720.6 101.8 55
Patient 9 419.5 101.7 54.9
Patient 10 536.7 101.9 55
Patient 11 869 100.1 54.1
Patient 12 529.7 100.8 54.4
Patient 13 589.8 99 53.5Page 4 of 7
(page number not for citation purposes)
Radiation Oncology 2008, 3:30 http://www.ro-journal.com/content/3/1/30Surgical results
Five of the 13 patients underwent a Whipple procedure.
One required a reconstruction of the portal vein; two
other procedures required a splenectomy, of which one
also included an en bloc resection of the left kidney. There
was no postoperative death, and only one patient suffered
from a complication (bilateral pneumonia, medically
treated). Two patients have no evidence of disease (one
patient in the 45 Gy cohort and one patient in 54 Gy
cohort). From the three remaining patients in the group
with resection, one had an omental metastasis at surgery
and received gemcitabine thereafter, and the other two
presented with local failure and/or metastases, so a treat-
ment with systemic gemcitabine was started.
Long-term outcome and survival
The overall median survival for the 13 study patients was
20.3 months. Three of 5 patients in the 45 Gy cohort were
operated on, and 2 of 6 in the 54 Gy cohort. The median
disease free and 2-year overall survival for the group with
resection was 12.6 months and 39%. Three patients are
alive at the time of this report and 2 of them have no evi-
dence of disease (1 patient in the 45 Gy cohort and 1
patient in 54 Gy cohort). They both underwent a com-
plete surgical resection. The third patient is currently
treated with gemcitabine and has a stable disease.
Discussion
The primary objective of this trial was to determine the
MTD of escalating doses of radiation therapy that could be
delivered concurrently with a fixed dose of gemcitabine
(300 mg/m2), administered on a weekly basis, within the
same overall treatment time. We have concluded that a
dose escalation to 54 Gy in 1.8 Gy fractions in an acceler-
ated fractionation regimen was the MTD. GI toxicity was
the DLT. Therefore we do not recommend this dose for
further investigation.
Varying doses and schedules of gemcitabine and concom-
itant RT for patients with locally advanced pancreatic can-
cer have been investigated, mainly in phase I clinical trials
[16,18-20]. Gemcitabine 300 – 600 mg/m2/week given as
a once weekly infusion concurrent with conventional RT
of 50.4 Gy was reported to be reasonably well tolerated
with some indication of anti-tumour activity [13,15,16].
In a phase I study by McGinn et al. to find the MTD of
gemcitabine in association with RT to 50.4 Gy in 1.8 Gy
daily fractions in patients with locally advanced non-
resectable pancreatic cancer, a DLT was reported in 3 of 13
patients [21]. Ten patients did not experience a DLT at the
following dose levels: 200 mg/m2 (3 patients), 300 mg/m2
(4 patients) and 400 mg/m2 (3 patients). One patient had
a DLT as a result of grade 3 neutropenia at a dose of 300
mg/m2 gemcitabine weekly. The most frequently reported
toxicities were GI (nausea and vomiting). Therefore a dose
of gemcitabine 300 mg/m2 on a weekly basis was chosen
in our study. This was a precaution measure, to take into
account the expected additional toxic effects of gemcitab-
ine concurrently with dose-escalated accelerated RT.
Despite this, the escalation to a 54 Gy dose level in an
accelerated regimen was shown to be not feasible.
McGinn et al. published the results of a phase I trial where
the investigators also combined a fixed weekly dose of
gemcitabine (1000 mg/m2) with an escalating dose of RT
[20]. Escalation was achieved by increasing the fraction
size in increments of 0.2 Gy, keeping the duration of radi-
ation constant at 3 weeks. The starting dose was 30 Gy (in
2 Gy fractions) and the final dose investigated (42 Gy in
2.8 Gy fractions) was not recommended for further study
considering the (potential) occurrence of both acute and
late toxicity. As in our study, the acute toxicity consisted of
dose-limiting GI toxicity. Application of the linear quad-
ratic model indicates that 42 Gy in 2.8 Gy-fractions is bio-
logically equivalent to 50.4 Gy in 1.8 Gy-fractions, a
standard dose and fractionation schedule used in the
treatment of patients with unresectable pancreatic cancer.
However, a radiation dose of 36 Gy in 2.4 Gy-fractions
was well tolerated and this is biologically equivalent to
approximately 41.4 Gy in 1.8 Gy-fractions with regard to
late effects. Also the radiation field size was defined much
smaller than radiation field sizes used in our CRT regi-
men, because the RT volume is the most critical variable
influencing GI toxicity in gemcitabine-based CRT regi-
Table 2: GI toxicity: The different GI toxicities experienced (nausea, vomiting and diarrhoea) for each dose cohort.
Gastro-intestinal (GI) toxicity
45 Gy cohort (7 patients) 54 Gy cohort (6 patients)
Nausea Vomiting Diarrhoea Nausea Vomiting Diarrhoea
Grade 0 0/7 1/7 5/7 0/6 0/6 2/6
Grade 1 2/7 4/7 2/7 0/6 3/6 3/6
Grade 2 5/7 2/7 0/7 3/6 2/6 1/6
Grade 3 0/7 0/7 0/7 3/6 1/6 0/6
Grade 4 0/7 0/7 0/7 0/6 0/6 0/6Page 5 of 7
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excess in local or regional failures by this reduction in
radiation dose and field size.
The inclusion of prophylactic nodal basins in the treat-
ment volume, resulting in a large volume of normal tissue
irradiated with increased radiosensitization of normal tis-
sues, in combination with the accelerated fractionation
and dose escalation, may have led to the toxicity pattern
described in our study. Therefore, it is recommended to
use guidelines for standardised treatment and volume
delineation. Efforts have been put to identify the elective
lymphatic target volume in pancreatic cancer and the large
topographic variability of upper abdominal lymphatics
may have consequences on PTV definition, resulting in an
adaptation of the treated volume [22,23]. Also, the adap-
tation of the PTV according to the dynamic MRI, to
account for the potential shift of the target volume due to
respiration, has led to an increased radiation volume
(mean PTV volume was 522.5 cm3). The recommended
dose level according to our results is 45 Gy in 1.8 Gy frac-
tions. When dose escalation in an altered fractionation
regimen is considered, this has to be performed more con-
servatively. Perhaps it would have been more feasible if
we had given an extra fraction in week 1, 3 and 5 in the
first dose escalation cohort to a total dose of 50.4 Gy, fol-
lowed by an evaluation of this group and then we could
have added one fraction per week.
Equally encouraging is the observation that the median
survival in this group of patients with a dismal prognosis
was 20.3 months, indicating that CRT may play a role in
the therapy of borderline resectable or unresectable LAPC.
Another important field of interest and future research
which may lead to a significant clinical impact on therapy
for this poor prognostic cancer, is the combination of
molecular targeted agents like nelfinavir [24] or erlotinib,
gefitinib and bevacizumab [25-27] with a CRT regimen,
although further confirmation of initial positive results in
phase I studies is warranted by randomised trials.
Conclusion
This gemcitabine-based CRT regimen with accelerated
dose escalation is clearly not feasible. GI toxicity is the
DLT. However, the median survival and the number of
inoperable patients becoming resectable, indicate that
there might be a role for the investigation of CRT with a
fixed dose of gemcitabine and concurrent RT with small
fractions (1.8 Gy/day) in borderline resectable or unre-
sectable non-metastatic LAPC.
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